Adjust Font Increase Font Decrease Font
  • Email
  • Print
  • RSS Feed

Media Releases

Statement to Physician Payments Sunshine Act Final Rule
WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.” About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies...
Read more

Latest Releases

Statement to Physician Payments Sunshine Act Final Rule
2/1/2013
WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.”
More
Pharmaceutical Organizations Announce Key Principles to Foster Supply Chain Security and Integrity
1/30/2013
Washington, D.C. (January 30, 2013) The 100th meeting of the National Conference of Pharmaceutical Organizations (NCPO) resolved that the member organizations will work together to help further secure the pharmaceutical supply chain.
More
Washington State Research Institutions Have Conducted More Than 3,600 Clinical Trials of New Medicines Since 1999
1/30/2013
Biopharmaceutical Companies Hired Them To Do The Tests
WASHINGTON, D.C. (January 29, 2013) – Working in collaboration with university medical schools and science centers, local hospitals and clinical research centers, America’s biopharmaceutical companies have conducted 3,664 clinical trials of new medicines in Washington over the last 13 years, a new study shows.
More
Rotary International and PhRMA team up for “The World’s Biggest Commercial”
1/25/2013
Leading trade group contributes $50,000 to Rotary to protect children from polio paralysis
Evanston, Ill., USA (Jan. 24, 2013) – Rotary International’s innovative campaign to develop the World’s Biggest Commercial to raise public awareness about polio eradication has struck a chord with the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
Robust Biopharmaceutical Pipeline Offers New Hope for Patients
1/17/2013
Report underscores value of innovation for patients with unmet medical needs
Washington, D.C. (January 17, 2013) — The biopharmaceutical pipeline is innovative and robust, with a high proportion of potential first-in-class medicines and therapies targeting diseases with limited treatment options, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
More
PhRMA Applauds Passage of Russia PNTR
12/6/2012
Washington, D.C. (December 6, 2012) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani issued the following statement today: “We applaud Congress for approving Permanent Normal Trade Relations (PNTR) for Russia. Improving trade relationships with Russia will protect and bolster U.S. biopharmaceutical jobs and exports.
More

Subscribe to our Email Updates